We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Ex Vivo T-Cell Depletion of Mobilized Peripheral Blood Stem Cells Via CD34-Selection (EXCESS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01189786
Recruitment Status : Recruiting
First Posted : August 27, 2010
Last Update Posted : December 20, 2022
Sponsor:
Collaborators:
Center for Cell and Gene Therapy, Baylor College of Medicine
The Methodist Hospital Research Institute
Information provided by (Responsible Party):
Robert Krance, Baylor College of Medicine

Tracking Information
First Submitted Date  ICMJE August 25, 2010
First Posted Date  ICMJE August 27, 2010
Last Update Posted Date December 20, 2022
Actual Study Start Date  ICMJE October 2010
Estimated Primary Completion Date October 2025   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: April 26, 2018)		 For Cohort 1: the rate of primary engraftment 50 days post SCT [ Time Frame: 50 days ]
Primary engraftment is defined as achievement of absolute neutrophil count (ANC) is greater than or equal to 500/ul for three consecutive days by day 50 post transplant. The treatment regimen will be considered clinically useful if the primary engraftment rate is at least 85%.
Original Primary Outcome Measures  ICMJE
 (submitted: August 25, 2010)		 To estimate the rate of stable engraftment [ Time Frame: 5 years ]
To estimate the rate of stable engraftment, early post SCT toxicity and incidence of GvHD in recipients of G-CSF mobilized peripheral blood stem cells depleted of T cells by positive selection for the CD34 antigen
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: April 26, 2018)
  • For Both Cohorts: The total incidence of overall acute GvHD (greater than or equal to grade 3) [ Time Frame: 100 days ]
    The overall incidence of acute GvHD will be measured 100 days post stem cell transplant. The regimen will be considered acceptable if aGvHD greater than or equal to grade 3 rate is at least 10% or lower.
  • Assessment of Long Term Survival [ Time Frame: 1 year ]
    Long term survival of recipients of G-CSF mobilized peripheral blood stem cells depleted of T cells by positive selection for the CD34+ antigen
Original Secondary Outcome Measures  ICMJE Not Provided
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Ex Vivo T-Cell Depletion of Mobilized Peripheral Blood Stem Cells Via CD34-Selection
Official Title  ICMJE Ex Vivo T-Cell Depletion of Mobilized Peripheral Blood Stem Cells Via CD34-Selection (EXCESS)
Brief Summary

Participants are being asked to take part in this study because treatment of his or her disease requires a stem cell transplant. Stem cells or "mother" cells are the source of normal blood cells and lead to recovery of blood counts after bone marrow transplantation. Unfortunately, there is not a perfectly matched stem cell donor (like a sister or brother) for the participant and his or her disease does not permit enough time to identify another donor (like someone from a registry list that is not his or her relative) or another suitable donor has not been identified. However, a close relative of the patient has been identified whose stem cells are not a perfect match, but can be used.

Alternatively, the patient may have already received a stem cell transplant but have evidence of mixed chimerism, which means some of the patient's own bone marrow cells are present, rather than all of the donor's cells. This may lead to an increased risk of the disease coming back. Or, the patient may have all donor cells but his or her bone marrow is not working very well, which may lead to frequent blood or platelet (cells that help in clotting blood) transfusions or infection.

Regardless of the reason, it may be necessary to isolate stem cells from a haploidentical (half-match) donor in order to provide bone marrow function. Because the stem cells from the donor are only half-matched to the participant, the risk of graft-versus-host disease (GvHD) is very high. GvHD is a complication after transplant caused by donor T cells (graft) that attack the transplant recipient, and this complication can cause death after transplant. Thus, it is important that the donor's blood cells are treated to minimize cells that are most likely to attack the host's tissues. This is done by using a special device to capture the CD34+ stem cells from the donor's stem cell product prior to giving the cells to the host. This method minimizes the donor T cells, which are responsible for causing GvHD.

Purpose: In an effort to lower the occurrences and severity of graft-versus-host disease in patients and to lower the rate of transplant failure, investigators would like to specially treat the donor's blood cells to minimize the cells that are most likely to attack the patient's tissues.
Detailed Description

Participation in this project will last approximately one year with follow-up exams.

Before treatment can begin, stem cells will be collected from the donor (a close relative) that has been selected as the best match for the participant. White blood cells will be collected from the donor. The cells will then be mixed with a special protein, called a CD34 antibody, that binds to the stem cells, which will then be separated out from the white blood cells by a special machine- called a CliniMACS CD34 Reagent System in the laboratory. This is an investigational device that is not approved by the FDA. Although this device is not approved for use in this country, it has been in use for years and is approved in other countries. The stem cells will be collected and frozen before they will be given to the participant.

On about days 28, 100 and 365 after the transplant, the participant will have the same tests/evaluations since the time of transplant; however, the participant will also have a bone marrow aspirate. This is where samples of bone marrow are taken to evaluate the participant's disease and Graft vs. Host Disease (GvHD) status. For patients who do not develop GvHD, they may have an additional bone marrow aspirate about a year after transplant.

In addition, for purposes of the study, health-related information will be collected for a year from the time of stem cell infusion. This will be used to determine survival, relapse, infections and GvHD that may occur following transplant.
Study Type  ICMJE Interventional
Study Phase  ICMJE Not Applicable
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE
  • Stem Cell Transplant
  • Allogeneic
Intervention  ICMJE Device: CliniMACS CD34 Reagent system
A special machine that separates out the donor cells that have been mixed with a special protein, CD34 antibody, that binds to the stem cells from the white blood cells.
Study Arms  ICMJE
  • Experimental: Cohort 2: CD34+ cells as a top off
    Cohort 2 consists of patients needing additional CD34+ stem cells collected by 'CliniMACS CD34 Reagent system' as a "topoff" without the need for additional conditioning prior to the infusion. These patients who have already received SCT and are receiving CD34+ cells from their original donor for poor graft function, declining chimerism or disease relapse.
    Intervention: Device: CliniMACS CD34 Reagent system
  • Experimental: Cohort 1: CD34+ Cells for transplant
    Cohort 1 consists of patients receiving CD34+ selected peripheral blood stem cell transplant with a preceding conditioning regimen (chemotherapy with, or without, radiation). The stem cells will then be separated out from the white blood cells by a special machine- called a CliniMACS CD34 Reagent System in the laboratory.
    Intervention: Device: CliniMACS CD34 Reagent system
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: April 27, 2017)		 144
Original Estimated Enrollment  ICMJE
 (submitted: August 25, 2010)		 20
Estimated Study Completion Date  ICMJE November 2026
Estimated Primary Completion Date October 2025   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion criteria for Stem Cell Transplant WITH Conditioning (COHORT 1)

The following must be answered YES for a patient to eligible to participate in study:

  1. Patient requiring allogeneic SCT
  2. Age between birth and 70 years
  3. Patient and/or responsible person able to understand and sign consent

Exclusion criteria for Stem Cell Transplant WITH Conditioning (COHORT 1)

The following must be answered NO for a patient to be eligible to participate in study:

  1. Active, acute GvHD > grade II or extensive, chronic GvHD
  2. Severe life, threatening infection
  3. Pulmonary dysfunction (FEV1, FVC or DLCO 40% of predicted or 3 SD below normal)
  4. Cardiac dysfunction (LVSF less than 25%)
  5. Psychiatric disturbance
  6. Lansky or Karnofsky score < 50%
  7. The presence of severe hepatic disease (direct bilirubin >3x upper limit of normal and AST > 5x upper limit of normal).
  8. Creatinine > 3x normal
  9. Known HIV Positivity
  10. Pregnancy

Inclusion Criteria for CD34+ Topoff WITHOUT conditioning (COHORT 2)

The following must be answered YES for a patient to be eligible to participate in study:

  1. Allogeneic SCT Recipient requiring additional cellular therapy
  2. Age between birth and 70 years
  3. Patient and/or responsible person able to understand and sign consent

At least ONE of the following must be answered YES for a patient to be eligible to receive CD34+ topoff:

  1. Evidence of mixed chimerisms (less than 95% donor cells)
  2. Evidence of poor bone marrow function (bone marrow cellularity less than 50% with at least one cytopenia)
  3. Relapsed or persistent disease

Exclusion criteria for CD34+ Topoff WITHOUT conditioning (COHORT 2)

The following must be answered NO for a patient to be eligible to participate in study:

  1. Active, acute GvHD > grade II or extensive, chronic GvHD
  2. Severe life, threatening infection
  3. Known HIV positivity
  4. Pregnancy
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE up to 70 Years   (Child, Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Robert Krance, MD 832-824-4661 rakrance@txch.org
Contact: Marlen Dinu 832-824-4881 mxdinu@txch.org
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT01189786
Other Study ID Numbers  ICMJE 27251-EXCESS
EXCESS ( Other Identifier: Baylor College of Medicine )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Current Responsible Party Robert Krance, Baylor College of Medicine
Original Responsible Party Helen Heslop, M.D, Center for Cell and Gene Therapy
Current Study Sponsor  ICMJE Baylor College of Medicine
Original Study Sponsor  ICMJE Same as current
Collaborators  ICMJE
  • Center for Cell and Gene Therapy, Baylor College of Medicine
  • The Methodist Hospital Research Institute
Investigators  ICMJE
Principal Investigator: Robert Krance, MD Baylor College of Medicine
PRS Account Baylor College of Medicine
Verification Date December 2022

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP